Competitive antagonists shift the dose-effect curve for an agonist (e.g. the endogenous neurotransmitter) to the right, but this effect can eventually be overcome by enough agonist concentration.
Related content
Genetics in Parkinson’s disease – coming to the fore of day-to-day clinical and research practice
This article discusses the major developments that have taken place in the PD genetics field, and provides an understanding of why and how genetics is increasingly being integrated into day-to-day clinical and research practice.
05.03.2025
Parkinson’s Disease
Substance Use Disorders and Behavioral Addictions with Special Consideration of Psychiatric Comorbidity
Individuals with addictive disorders frequently have medical and (underlying) psychiatric comorbid conditions and high disease burden
26.02.2025
Substance Use Disorders
Perceived caregiver burden as Parkinson’s disease advances
There are many aspects of Parkinson’s disease (PD) that can intensify the caregiver burden
22.02.2025
Parkinson’s Disease